Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043244 | 1.00 | EPHX2 (0.45) | EPHX2ELANEVNN1HIF1APTGDR2 | |
| SCHEMBL5041133 | 0.92 | EPHX2 (0.45) | EPHX2ELANEVNN1HIF1APTGDR2 | |
| SCHEMBL5041134 | 0.92 | EPHX2 (0.45) | EPHX2ELANEVNN1HIF1APTGDR2 | |
| SCHEMBL5043091 | 0.88 | EPHX2 (0.45) | EPHX2ELANEVNN1PTGDR2RORC | |
| SCHEMBL5043090 | 0.88 | EPHX2 (0.45) | EPHX2ELANEVNN1PTGDR2RORC | |
| SCHEMBL5041962 | 0.86 | PKM (0.50) | EPHX2VNN1HIF1APKM | |
| SCHEMBL5040763 | 0.86 | HIF1A (0.43) | EPHX2HIF1APKM | |
| SCHEMBL5040766 | 0.86 | HIF1A (0.43) | EPHX2HIF1APKM | |
| SCHEMBL5041968 | 0.86 | PKM (0.50) | EPHX2VNN1HIF1APKM | |
| SCHEMBL5047829 | 0.85 | HIF1A (0.44) | VNN1HIF1APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | EPHX2 1557/4885ELANE 95/4885VNN1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.